Oral immunization with Lactococcus lactis PppA (LPA +), a recombinant strain that is able to express the pneumococcal protective protein A, can improve the resistance to respiratory challenge with Streptococcus pneumoniae in adult mice. In this study, we investigated whether oral immunization protocols using LPA+ are able to protect young mice against pneumococcal respiratory infection. METHODS: Young mice (aged, 3 weeks) were immunized orally with LPA+ for 5 consecutive days. Vaccination was performed once (non-boosted group), or twice with a 2-week interval between each immunization (boosted group). At the end of treatment, the specific immune responses and the resistance to pneumococcal infection were studied. RESULTS: We found that the oral immunization with LPA+ was able to induce the production of specific antibodies in the respiratory and intestinal tracts as well as systemically. Analysis of IgG subtypes showed that LPA+ immunization stimulated a mixed Th1 and Th2 response. To assess whether the production of mucosal and systemic antibodies was able to afford protection against respiratory pneumococcal infection, challenge experiments with the pathogenic serotypes 3, 6B, 14, and 23F were carried out. Vaccination with LPA+ was able to increase resistance to infection with the four serotypes of S. pneumoniae, although the protective capacity of the experimental vaccine was different for each of them. Immunization decreased colonization in the lung, prevented bacteremia of serotypes 6B, 14, and 23F, and decreased colony counts of serotype 3. CONCLUSION: We have shown that the oral immunization of young mice with LPA+ effectively induces the production of specific antibodies against the antigen PppA, both in mucosae and at the systemic level.
Introduction
Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide. It asymptomatically colonizes the upper respiratory tract in approximately 50% of young children under the age of 2 years. 1, 2 In addition, this pathogen is a leading cause of bacterial meningitis, sepsis, pneumonia, and otitis media in young children. 3, 4 This problem is exacerbated by the increasing emergence of multiple-antibiotic-resistant strains, an important worldwide issue since infants are colonized very early by resistant strains, especially in developing countries. 2 This fact has stimulated renewed interest in the prevention of pneumococcal infections using vaccines. Three avenues of pneumococcal vaccination have been explored: (1) polysaccharide vaccines; (2) protein-polysaccharide conjugate vaccines; and (3) recently, new vaccine strategies focused on the use of pneumococcal surface-associated proteins. This third strategy is the most desirable because immunizations with these antigens would elicit protection in high risk groups like children; and this vaccine would be serotype independent and cheap to produce. 1 However, mucosal immunization has been limited because of inefficient antigen uptake, tolerance induction, and proteolytic degradation of antigens before they reach the immune cells. Thus great efforts have been made in recent years to combine mucosal delivery with agents that have intrinsic adjuvant activity. In this sense, lactic acid bacteria represent an interesting alternative for the development of mucosal vaccines, especially because they possess well documented immuno-enhancing properties. [5] [6] [7] [8] [9] The lactic acid bacterium model, Lactococcus lactis NZ9000, has been extensively engineered for the production of heterologous proteins using the nisin-controlled gene expression system. 10 We demonstrated that this strain, administered by the oral route, is able to improve the innate and specific immune responses in the respiratory tract. 11 In addition, we used the nisin-controlled gene expression system, as well as the signals of the lactococcal Usp45 secretion peptide and of the cell wall anchoring protein M6 from Streptococcus pyogenes, to develop a recombinant strain of L. lactis able to express the pneumococcal protective protein A (PppA) on its surface after induction with nisin. 12 We showed that oral immunization with the recombinant L. lactis PppA strain was able to induce the production of both systemic and mucosal (intestinal and respiratory) antibodies in adult immunocompetent mice. 13 Moreover, oral vaccination with L. lactis PppA strain improved the resistance of adult mice to respiratory challenge with different pneumococcal serotypes. 13 Infectious disease is a major cause of human infant mortality. There are over 2.2 million annual deaths in children between the ages of 1 and 6 months. The infectious agents responsible for these deaths may produce acute respiratory infections (e.g. respiratory syncytial virus, Bordetella pertussis, Haemophilus influenzae B, S. pneumoniae) or diarrheal disease (e.g. rotaviruses, Salmonella spp., Shigella spp.). 14, 15 Consequently, one of the major challenges in vaccinology is the development of products that are able to induce protective immunity in the early life period. Most experimental vaccines designed to prevent pneumococcal infections have been studied in infection models with adult immunocompetent mice with a view to their future application to high risk populations (children, the elderly and immunocompromised individuals). Thus the objective of this work was to find out if the oral immunization protocols with L. lactis PppA that are effective in inducing protective immunity in adult mice are able to protect young mice against pneumococcal respiratory infection.
Methods

Immunization procedures
Male Swiss albino mice (aged, 3 weeks) were obtained from the closed colony at Centro de Referencia para
The antibodies produced may play an important role in the protection against pneumococcal disease, since the young mice immunized with the experimental vaccine showed an increased resistance to infection with different serotypes of the pathogen. 
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Antibody avidity assay
For the measurement of IgM, IgA, and IgG antibody avidity, the Enzyme-linked immunosorbent assay method was used. After samples were incubated, plates were washed and incubated for 15 minutes at room temperature with 0.5 M sodium thiocyanate (NaSCN) to induce the dissociation of the antigen-antibody complexes. Plates were washed, and the remaining incubations were performed as described above without modification. The avidity index for each sample was determined as follows: the antibody concentration in the presence of the chaotropic agent NaSCN was divided by the antibody concentration in the absence of NaSCN and multiplied by 100.
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Opsonophagocytosis assay
Opsonophagocytic activity of BAL, IF, and serum antibodies were determined by measuring the killing of live pneumococci by peritoneal macrophages in the presence of antibodies and complement. 13 Isolation of peritoneal macrophages was performed as follows: mice (aged 6 weeks) were anesthetized and sacrificed by cervical dislocation. The peritoneal cavity was flushed with 5 mL of RPMI 1640 medium (Sigma 
Bacterial cell counts in lung and blood
Lungs were excised, weighed, and homogenized in 5 mL of sterile peptone water. Homogenates were diluted appropriately, plated in duplicate on blood agar and incubated for 18 hours at 37°C. S. pneumoniae colonies were counted and the results were expressed as log 10 CFU/g of organ. Progression of bacterial growth to the bloodstream was monitored using blood samples obtained by cardiac puncture with a heparinized syringe. Samples were plated on blood agar and bacteremia was reported as either negative or positive hemocultures after incubation for 18 hours at 37°C.
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Statistical analysis
Experiments were performed in triplicate and results were expressed as mean ± standard deviation. After verification of a normal distribution of data, 2-way analysis of variance was used. For pairwise comparisons of the means, Tukey's test was used. Differences were considered significant at p < 0.05.
Results
L. lactis PppA + vaccination induced specific antibodies in serum and intestinal fluid
To evaluate the ability of L. lactis PppA + to stimulate the immune system associated with the intestinal mucosa, the levels of IgA-type anti-PppA antibodies were studied first. The two oral immunization protocols with L. lactis PppA + induced the production of specific antibodies in intestinal fluid, although the immunization protocol designed with two stimulations, 14 days apart from each other, more efficiently induced the production of IgAtype anti-PppA antibodies in the gut (Table 1) . No antibodies were found in the groups treated with the recombinant bacterium without boosting (L. lactis PppA−) or with nonfat milk. Oral immunization with L. lactis PppA + also induced the production of specific antibodies in serum, while no serum antibodies were found in the control groups (Table 1 ). In agreement with observations at the level of the intestinal mucosa, oral immunization with boosting induced the production of IgG-type antiPppA antibodies in serum more efficiently. We also studied the IgG1 and IgG2a levels induced by immunization with L. lactis PppA + , to assess the type of immunological response induced (Th1 or Th2), taking into account that Th1 cells secrete Interferon (IFN)-γ, and are associated with class switching to IgG2a, while Th2 cells secrete IL-4, IL-5 and IL-10 and promote class switching to IgG1. We observed that the oral administration of L. lactis PppA + induced a mixed Th1/Th2 response in the young mice, since the IgG1/IgG2a ratios were 1.5 ± 0.1 and 1.8 ± 0.3 for the boosted and non-boosted groups, respectively (Table 1) . 1D ) and, in this case, the protocol with boosting was also the most efficient. The oral administration of L. lactis PppA− also increased the number of IgA + cells in both intestine and lung, which confirms our previous results showing that the non-recombinant strain is able to stimulate the IgA cycle. 11 Since the administration of L. lactis
PppA + induces the mobilization of IgA + B lymphocytes from the intestine to the lungs, this treatment should be capable of increasing the levels of anti-PppA IgA in the respiratory tract. To verify this, we determined the levels of these antibodies in BAL. Bearing in mind that other immunoglobulins can diffuse from the serum toward the pulmonary alveoli, and that they have an important role in respiratory defenses, we also determined the levels of IgM and IgG anti-PppA in BAL. After oral immunization with L. lactis PppA + , we detected specific IgA, IgM and IgG antibodies in BAL ( Table 2 ). The vaccine plus boosting protocol was the most efficient in increasing the levels of anti-PppA antibodies in the respiratory mucosae. This effect was evidenced by the IgG and IgA concentrations in BAL, which were significantly higher in this group than in the animals without boosting ( Table 2 ). The IgG1/IgG2a ratios in the respiratory tract also indicated the stimulation of a mixed Th1/Th2 response ( Table 2 ).
Avidity and opsonophagocytic activity of anti-PppA antibodies
The avidities of the BAL, IF, and serum antibodies are shown in Figure 2 . The avidity of the IF antibodies in the non-boosted L. lactis PppA + group were below 40% for both IgM and IgG antibodies, although IgA anti-PppA reached values close to 60% (Figure 2A ). Boosting in creased the avidity of the IgG and IgA antibodies in IF, the latter reaching an average of 80%, which was the highest value observed in our study. Primary immunization with L. lactis PppA + induced the production of antiPppA IgM, IgG, and IgA antibodies in BAL with avidities lower than 50% ( Figure 2C ). Boosting with L. lactis PppA + increased the avidity of BAL IgG and IgA, but did not induce changes in IgM antibody avidity. Mice in the boosted L. lactis PppA + group also showed serum anti bodies with higher avidity than mice in the nonboosted L. lactis PppA + group ( Figure 2B) . Study of the opsonophagocytic activity of the anti-PppA antibodies showed that mice in the non-boosted L. lactis PppA + group had low titers in serum and BAL (Figure 3 ). Boosted animals showed significantly higher titers in serum, BAL, and IF (Figure 3 ). 
Safety of L. lactis PppA + immunization
To assess the safety of L. lactis PppA + immunization in infant mice, weight gain and the number of deaths were monitored daily. No deaths occurred, and weight gain was observed in infant mice immunized with the experimental vaccine compared with the unimmunized mice (data not shown).
Protective capacity of L. lactis PppA + vaccination
Considering that the immunization protocol with boosting proved to be more effective in inducing systemic and mucosal specific anti-PppA antigen antibodies, and in mobilizing the IgA + cells from the inductor sites of the immune system in the intestinal mucosae toward the lungs, we decided to assess the effectiveness of this immunization scheme in providing protective immunity. Since cross-protection is an essential characteristic of a widely successful pneumococcal vaccine, a variety of pneumococcal strains need to be tested to prove the effectiveness of the vaccine construct. Thus the ability of oral immunization with L. lactis PppA + to confer cross protective 
a Data presented as mean ± standard deviation; *significantly different from the non-boosted group at the same time point (p < 0.05). ND = not determined.
immunity to the young mice was evaluated with serotypes 3, 6B, 14, and 23F. These serotypes were selected according to epidemiological studies that determined that serotype 14 is the prevailing one in our country, 20 and also taking into account that serotypes 3, 6B, 9, 14, 18, 19, and 23F are the ones most often associated with invasive disease. 21 Young mice were challenged intranasally with virulent pneumococcal serotypes 2 weeks after the last vaccine dose, and the development of pneumococcal disease was evaluated 48 hours after infection. In the control animals without treatment, all the S. pneumoniae serotypes used were detected in the lung cultures and hemocultures 2 days after challenge (Table 3) . These results indicate that the four serotypes of the pathogen were able to colonize the respiratory tract and spread to the blood stream. However, the bacterial counts for serotype 3 in the lung were higher by one order of magnitude compared with serotype 6B, and by two orders of magnitude compared with serotypes 14 and 23F. The mice immunized with L. lactis PppA + by the oral route showed bacterial counts in the lung that were significantly lower than their respective controls (Table 3) . Oral immunization with the recombinant oral bacteria was effective in limiting the dissemination of serotypes 6B, 14, and 23F, since the hemocultures in these groups were negative. However, the oral administration of L. lactis PppA+ to infant mice did not prevent bacteremia caused by serotype 3, which would be related to the greater virulence of this strain in our experimental model. Oral treatment with L. lactis PppA-improved resistance to pneumococci, but its protective effect was significantly lower than that observed in the L. lactis PppA + groups (Table 3 ). This fact is probably related to our previous observation showing that the strain L. lactis NZ9000 has the capacity to activate both the innate and specific immune response in the respiratory tract when administered by the oral route at the proper dose.
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Discussion
Orally administered vaccines have the distinct advantage of being able to potentially reach the highly concentrated gut associated lymphoid tissue, and induce both serum and secretory immune responses. 22 Thus, unlike systemic immunization; oral delivery can induce mucosal and systemic immune responses. Vaccination in early life may be important in protecting the individual later on. For example, it is difficult to effectively protect elderly people (one of the most vulnerable groups in the population) due to age-related changes in the immune system (immunosenescence). Vaccination, or exposure to a given disease, early in life has been shown to confer a certain level of immunological memory in later life. 23 In this study, we
showed that the oral immunization of young mice with the recombinant lactic acid bacteria, L. lactis PppA + , was able to induce the production of specific antibodies both in the intestinal tract and at the systemic level. The efficient stimulation of the gut mucosal immune system by L. lactis PppA + was evidenced by the increase in the number of IgA + cells in the intestine, and by the production of specific anti-PppA IgA antibodies in the IF. We also observed an efficient stimulation of the systemic immune response after vaccination with L. lactis PppA + , which was evidenced by the detection of specific antiPppA IgG antibodies in the serum. Recent in vitro studies showed that L. lactis NZ9000 has intrinsic adjuvant properties, since it is able to stimulate the maturation of dendritic cells derived from bone marrow, and to induce the production of cytokines with adjuvant properties such as IL-1β. 24 Moreover, previous in vivo studies in our lab demonstrated that this lactic acid bacterium is able to stimulate both intestinal and systemic immunity when administered at the appropriate dose. 11 These properties of L. lactis NZ9000 would explain the efficacy of oral immunization with L. lactis PppA + in stimulating specific immune responses against the S. pneumoniae antigen in young mice. The analysis of IgG subtypes showed that L. lactis PppA + immunization stimulated a mixture of Th1 and Th2 responses, which is consistent with our previous studies in adult mice in which we observed that oral immunization with L. lactis PppA + was able to induce the production of IL-4-and IFN-γ-producing spleen cells. 13 These findings were confirmed recently by other authors, who demonstrated that L. lactis NZ9000 is able to stimulate the production of both IL-12 and IL-10 by bone marrow derived dendritic cells in vitro. 24 It has been demonstrated that oral vaccination can be used to induce protective immunity in distant mucosal sites. The protective effect in those sites mediated by oral vaccines is possible because of the existence of a common mucosal immune system. When the mucosal immune response is induced, primed T and B cells migrate through the lymphatic system and enter the peripheral blood circulation via the thoracic duct. Extravasation of immune cells occurs not only in the gut lamina propria, but also in other mucosal sites such as the respiratory tract. 25 Thus this homing pathway of primed lymphoid cells from the inductive sites on the Peyer's patches to distant mucosal sites after antigen stimulation could be exploited to design recombinant L. lactis-derived oral vaccines that could afford protection against respiratory pathogens. 6 In this study, we demonstrated that the oral immunization of young mice with L. lactis PppA + induced the production of specific IgA and IgG antibodies in the respiratory tract. The relative pro portion of immunoglobulins in the upper respiratory tract differs substantially from that in the lower respiratory tract; IgA prevailing in the former and IgG in the latter. 26 That is why the presence of both immunoglobulin types with specificity for antigens of S. pneumoniae is necessary to provide better protection of the airways. Anti-pneumococcal IgA would reduce the colonization of the respiratory tract because of its capacity to limit the attachment of the pathogen to the epithelial cells, while anti-pneumococcal IgG would have a protective role in the alveoli by promoting phagocytosis, and by preventing local dissemination of the pathogen and its passage to the blood stream. 26 To assess whether the production of mucosal and systemic antibodies induced by oral immunization with L. lactis PppA + was able to afford protection against respiratory infection with S. pneumoniae, challenge experiments with the different serotypes of the pathogen were carried out. Bacterial counts in lung, coupled with hemocultures, allowed us to conclude that young mice are more susceptible than adult mice to respiratory S. pneumoniae infection, since pathogen counts in blood and lung were significantly higher than those previously found in adult mice. 13 Oral immunization of young mice with L. lactis
PppA + increased their resistance to infection with the four serotypes of S. pneumoniae, although the protective capacity of the experimental vaccine was different for each of them. Immunization decreased colonization in lung and prevented bacteremia of serotypes 6B, 14, and 23F, and decreased serotype 3 counts.
In conclusion, we have shown that the oral immunization of young mice with the recombinant lactic acid bacteria L. lactis PppA + effectively induces the production of specific antibodies against the PppA antigen of S. pneumonia, both in mucosae and at the systemic level. The antibodies produced play an important role in protection against pneumococcal disease, since young mice immunized with the experimental vaccine showed increased resistance to infection with different serotypes of the pathogen. The identification of effective and safe strategies for the induction of protective immunity in the early life period requires further research, but the use of selected efficacious vaccines could make a tremendous difference in terms of infant survival worldwide. The results of the present paper show that oral immunization with recombinant bacteria represents a promising alternative for improving immunity in young individuals.
